In this study, we demonstrate that COVID-19 ARDS survivors who 6-months after ICU-discharge showed signs of alteration of the alveolar-capillary membrane, assessed by a reduction in the DmCO/VA ratio, have a higher expression of TGF-β1 active in both peripheral blood and respiratory tract. The gene discussed is TGFB1; the disease is COVID-19.